Displaying 1–25 of 221 results for Paul Thomas, Managing Editor
Director Michael Moore is pointing his lens toward the pharmaceutical industry, and drug company employees are on high alert. Love Moore or hate him, enjoy the limelight while it lasts, says Managing Editor Paul Thomas. Besides, an encounter might also be an opportunity to talk about the positive...
Stable isotopic analysis is already being used in pharmaceutical and raw material authentication, but spectrometry based on the technique promises to become a useful PAT tool. In this exclusive interview, John Jasper, CSO of Molecular Isotope Technologies, discusses the technology with Managing ...
Middle managers in pharma today have a tough, thankless jobbut someones got to do it, and many do it well.
Organizations with built-in risk management frameworks allow middle managers to thrive, says Scott Chizzo, Maxiom Groups president and chief consultant, in this exclusive interview.
RFID can wait. Lets watch barcoding come into its own, suggests Managing Editor Paul Thomas.
The drug importation issue: Stopping prescription drug shipments to online Canadian pharmacies only diverts attention from key safety and affordability issues, and a clear solution: track and trace technologies.
While truly groundbreaking innovations in chromatography equipment happen every blue moon, there have been noteworthy gradual improvements in the areas of chromatography media, column packing and on-line buffer blending. Managing Editor Paul Thomas provides the big picture.
Managing Editor Paul Thomas discusses how hiring initiatives that focus on women and minorities may miss the big picture.
Managing Editor Paul Thomas discusses "big ideas" in flu pandemic preparedness, including a "national guard" for vaccine distribution.
Industry consultant Jane Chin examines what makes the jobs of pharmas middle managers so tough, and how they can succeed against the odds.
With real-time, wireless and other new monitoring technologies, pharma gains better control of temperature, pressure, humidity, and more.
If Ashton Kutcher were in pharma, hed be on LinkedIn.
If the serial acquirers dont kill us, theyll make us stronger.
The annual spring tradeshow has reenergized itself by building a year-round online presence.
As paradigms shift, we also need paradigm expansion.
Probabilistic rather than deterministic modeling is essential, says Quintiles Davis Walp.
GlaxoSmithKline recently announced an item-level RFID pilot, and has begun tagging bottles of its Trizivir HIV medication, a common target for counterfeiting and diversion. GSK follows Pfizer (the "Little Blue Pill") and Purdue Pharma (Oxycontin) to detail item-level pilots. In this exclusive ...
Theres nothing like a good tale of frugality to make your day.
Makers of drugs for lethal injection face pressure to spurn U.S. prisons.
Communities can partner with manufacturers, but they cant apply pressure.
"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way.
Pharma's middle managers carry on despite a "damned if we do, damned if we don't" environment.
Novartis has made responsible energy usage part of its modus operandi, says Environment and Energy Manager Markus Lehni.
Consultant Steve Sawin answers our questions about managing contingent labor.
When it comes to operational excellence initiatives, middle managers are often seen as the problema black hole, if you willbut can be the solution.